A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy

被引:113
|
作者
O'Mahony, Constantinos [1 ,2 ]
Tome-Esteban, Maite [1 ]
Lambiase, Pier D. [1 ]
Pantazis, Antonios [1 ]
Dickie, Shaughan [1 ]
McKenna, William J. [1 ]
Elliott, Perry M. [1 ]
机构
[1] UCL, Heart Hosp, Inherited Cardiac Dis Unit, London W1G 8PH, England
[2] London Chest Hosp, London E2 9JX, England
关键词
IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; LEFT-VENTRICULAR HYPERTROPHY; BLOOD-PRESSURE RESPONSE; PROGNOSTIC VALUE; EUROPEAN-SOCIETY; TASK-FORCE; SURVIVAL; EXERCISE; THERAPY; IDENTIFICATION;
D O I
10.1136/heartjnl-2012-303271
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims Sudden cardiac death (SCD) is a common mode of death in hypertrophic cardiomyopathy (HCM), but identification of patients who are at a high risk of SCD is challenging as current risk stratification guidelines have never been formally validated. The objective of this study was to assess the power of the 2003 American College of Cardiology (ACC)/European Society of Cardiology (ESC) and 2011 ACC Foundation (ACCF)/American Heart Association (AHA) SCD risk stratification algorithms to distinguish high risk patients who might be eligible for an implantable cardioverter defibrillator (ICD) from low risk individuals. Methods and results We studied 1606 consecutively evaluated HCM patients in an observational, retrospective cohort study. Five risk factors (RF) for SCD were assessed: non-sustained ventricular tachycardia, severe left ventricular hypertrophy, family history of SCD, unexplained syncope and abnormal blood pressure response to exercise. During a follow-up period of 11 712 patient years (median 6.6 years), SCD/appropriate ICD shock occurred in 20 (3%) of 660 patients without RF (annual rate 0.45%), 31 (4.8%) of 636 patients with 1 RF (annual rate 0.65%), 27 (10.8%) of 249 patients with 2 RF (annual rate 1.3%), 7 (13.7%) of 51 patients with 3 RF (annual rate 1.9%) and 4 (40%) of 10 patients with >= 4 RF (annual rate 5.0%). The risk of SCD increased with multiple RF (2 RF: HR 2.87, p <= 0.001; 3 RF: HR 4.32, p=0.001; >= 4 RF: HR 11.37, p<0.0001), but not with a single RF (HR 1.43 p=0.21). The area under time-dependent receiver operating characteristic curves (representing the probability of correctly identifying a patient at risk of SCD on the basis of RF profile) was 0.63 at 1 year and 0.64 at 5 years for the 2003 ACC/ESC algorithm and 0.61 at 1 year and 0.63 at 5 years for the 2011 ACCF/AHA algorithm. Conclusions The risk of SCD increases with the aggregation of RF. The 2003 ACC/ESC and 2011 ACCF/AHA guidelines distinguish high from low risk individuals with limited power.
引用
收藏
页码:534 / 541
页数:8
相关论文
共 50 条
  • [1] Comparison of the Prognostic Usefulness of the European Society of Cardiology and American Heart Association/American College of Cardiology Foundation Risk Stratification Systems for Patients With Hypertrophic Cardiomyopathy
    Leong, Kevin M. W.
    Chow, Ji-Jian
    Ng, Fu Siong
    Falaschetti, Emanuela
    Qureshi, Norman
    Koa-Wing, Michael
    Linton, Nicholas W. F.
    Whinnett, Zachary I.
    Lefroy, David C.
    Davies, D. Wyn
    Lim, Phang Boon
    Peters, Nicholas S.
    Kanagaratnam, Prapa
    Varnava, Amanda M.
    AMERICAN JOURNAL OF CARDIOLOGY, 2018, 121 (03): : 349 - 355
  • [2] Validation of the new American College of Cardiology/American Heart Association Guidelines for the risk stratification of sudden cardiac death in a large Mediterranean cohort with Hypertrophic Cardiomyopathy
    Zegkos, Thomas
    Tziomalos, Georgios
    Parcharidou, Despoina
    Ntelios, Dimitris
    Papanastasiou, Christos A.
    Karagiannidis, Efstratios
    Gossios, Thomas
    Rouskas, Pavlos
    Katranas, Sotiris
    Paraskevaidis, Stilianos
    Karvounis, Haralambos
    Efthimiadis, Georgios
    HELLENIC JOURNAL OF CARDIOLOGY, 2022, 63 : 15 - 21
  • [3] Improvement in sudden cardiac death risk prediction by the enhanced American College of Cardiology/American Heart Association strategy in Chinese patients with hypertrophic cardiomyopathy
    Liu, Jie
    Wu, Guixin
    Zhang, Ce
    Ruan, Jieyun
    Wang, Dong
    Zhang, Mo
    Wang, Limei
    Yang, Yaoyao
    Li, Xinrong
    Wang, Yilu
    Hui, Rutai
    Zou, Yubao
    Kang, Lianming
    Wang, Jizheng
    Song, Lei
    HEART RHYTHM, 2020, 17 (10) : 1658 - 1663
  • [4] Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy
    Maron, Martin S.
    Rowin, Ethan J.
    Wessler, Benjamin S.
    Mooney, Paula J.
    Fatima, Amber
    Patel, Parth
    Koethe, Benjamin C.
    Romashko, Mikhail
    Link, Mark S.
    Maron, Barry J.
    JAMA CARDIOLOGY, 2019, 4 (07) : 644 - 657
  • [5] Hypertrophic Cardiomyopathy: New Evidence Since the 2011 American Cardiology of Cardiology Foundation and American Heart Association Guideline
    Fraiche, Ariane
    Wang, Andrew
    CURRENT CARDIOLOGY REPORTS, 2016, 18 (08)
  • [6] Hypertrophic Cardiomyopathy: New Evidence Since the 2011 American Cardiology of Cardiology Foundation and American Heart Association Guideline
    Ariane Fraiche
    Andrew Wang
    Current Cardiology Reports, 2016, 18
  • [7] RECOMMENDATIONS OF THE AMERICAN COLLEGE OF CARDIOLOGY, THE AMERICAN HEART ASSOCIATION AND THE EUROPEAN SOCIETY OF CARDIOLOGY (2006): ON THE MANAGEMENT OF PATIENTS WITH ATRIAL FIBRILLATION
    Fuster, V.
    Ryden, L. E.
    Cannom, D. S.
    Crijns, H. J.
    Curtis, A. B.
    Ellenbogen, K. A.
    Halperin, J. L.
    Le Heuzey, J. Y.
    Kay, G. N.
    Lowe, J. E.
    Olsson, S. B.
    Prystowsky, E. N.
    Tamargo, J. L.
    Wann, S.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2007, 3 (03)
  • [8] RECOMMENDATIONS OF THE AMERICAN COLLEGE OF CARDIOLOGY, THE AMERICAN HEART ASSOCIATION AND THE EUROPEAN SOCIETY OF CARDIOLOGY (2006) ON THE MANAGEMENT OF PATIENTS WITH ATRIAL FIBRILLATION
    Fuster, V.
    Ryden, L. E.
    Cannom, D. S.
    Crijns, H. J.
    Curtis, A. B.
    Ellenbogen, K. A.
    Halperin, J. L.
    Le Heuzey, J. Y.
    Kay, G. N.
    Lowe, J. E.
    Olsson, S. B.
    Prystowsky, E. N.
    Tamargo, J. L.
    Wann, S.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2007, 3 (02) : 72 - 97
  • [9] Comparison of the American College of Cardiology/American Heart Association and the European Society of Cardiology Guidelines for the Management of Patients With Valvular Heart Disease
    Alame, Aya J.
    Karatasakis, Aris
    Karacsonyi, Judit
    Danek, Barbara A.
    Sorajja, Paul
    Gossl, Mario
    Garcia, Santiago
    Jneid, Hani
    Kakouros, Nikolaos
    Martinez-Parachini, Jose Roberto
    Resendes, Erica
    Kalsaria, Pratik
    Roesle, Michele
    Rangan, Bavana V.
    Banerjee, Subhash
    Brilakis, Emmanouil S.
    JOURNAL OF INVASIVE CARDIOLOGY, 2017, 29 (09): : 320 - 326
  • [10] American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy - A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines
    Maron, BJ
    McKenna, WJ
    Danielson, GK
    Kappenberger, JKB
    Kuhn, HJ
    Seidman, CE
    Shah, PM
    Spencer, WH
    Spirito, P
    Cate, FJT
    Wigle, ED
    EUROPEAN HEART JOURNAL, 2003, 24 (21) : 1965 - 1991